CAG Funds’s CFO/MD visits DiaCarta in the U.S.

CAG Funds’s CFO/MD, Mr. Curtiz Lefkowitz, visits DiaCarta in the U.S. for a tour of their laboratory and facilities. CAG Funds is currently investing in bio-tech.

DiaCarta is a translational genomics and personalized diagnostics company based on the U.S. Their mission is to provide highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. With over 18,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.